🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Turkey / NCT07000604
Recruiting Not applicable

Effect of ınhaler Use on Oral Health in COPD Patients

NCT07000604 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2025-05-30
Last updated
2025-06-05

Condition(s) studied

Chronic Obstructive Pulmonary Disease (COPD)

Investigational drug(s) / intervention(s)

Mouth Care Training

Mouth Care Training: Patients will be educated on how to care for their mouths after using inhaled medication.

Study summary

The aim of this study was to evaluate the effect of oral health education given to individuals diagnosed with COPD and using inhaled medication.

Eligibility

Sex
ALL
Min age
35 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Diagnosed with COPD for at least 6 months, * Outpatient and inpatient, * Consent to participate in the research, * Not under the age of eighteen, * With a metered dose inhaler (MDI) in treatment, * No communication barriers, * No COPD exacerbation and/or respiratory tract infection, * According to the GOLD report; mild (Stage 1), moderate (Stage 2), severe (Stage 3). Exclusion Criteria: * Diagnosed with COPD for less than 6 months, * Refused to participate in the research, * Treatment without metered dose inhalers (MDIs), * Uncommunicative, * Those who withdrew from participating in the study during data collection, * Not completing the survey, * COPD exacerbation and/or respiratory tract infection,

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Çankiri Devlet Hastanesi Çankırı Turkey (Türkiye) Recruiting

More Çankırı Karatekin University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07000604 on ClinicalTrials.gov ↗ ← All trials in Turkey